Olympus Europe, the European subsidiary of the Japanese camera, microscopes and imaging systems manufacturer, has entered a partnership with Cytosurge. The two companies plan to develop new devices for experiments on single cells.
Olympus has years of experience in optimizing so-called live cell imaging systems, while Cytosurge, a spinoff from the Federal Institute of Technology in Zurich (ETH), has developed nanotechnology solutions for single-cell analysis. The company, which is headquartered in Glattbrugg, has already patented the underlying FluidFM. Now, the two companies are merging their expertise.
The aim of the partnership is to fight diseases by strengthening pharmaceutical research – in particular in the fields of stem cells, cancer cells and degenerative diseases. It will not only act as a catalyst for collective innovation, but also to accelerate penetration into the life sciences and pharmaceuticals market for Olympus and Cytosurge, according to a statement.